oru.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Treatment of hepatitis C virus infection for adults and children: updated Swedish consensus guidelines 2017
Department of Infectious Diseases, Institute of Biomedicine at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.ORCID iD: 0000-0002-7995-3626
Department of Infectious Diseases, Institute of Biomedicine at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Örebro University, School of Medical Sciences. Department of Infectious Diseases.ORCID iD: 0000-0001-7248-0910
Department of Medicine, Division of Infectious Diseases, Karolinska Institute at Karolinska University Hospital Huddinge, Stockholm, Sweden.
Show others and affiliations
2018 (English)In: Infectious Diseases, ISSN 2374-4235, E-ISSN 2374-4243, Vol. 50, no 8, p. 569-583Article, review/survey (Refereed) Published
Abstract [en]

Aim: Following the approval of two new therapeutic combinations within the European Union in 2017, the former Swedish recommendations for the treatment of hepatitis C virus (HCV) infection from 2016 were deemed in need of updating.

Materials and methods: An expert meeting to this end was held in Stockholm, Sweden in October 2017.

Results and conclusions: An interferon-free combination of direct-acting antiviral agents is now recommended for all patients with chronic HCV infection, regardless of liver fibrosis stage, in order to limit morbidity and spread of the disease. An extended discussion of treatment for people who inject drugs in order to diminish transmission is included.

Place, publisher, year, edition, pages
Taylor & Francis, 2018. Vol. 50, no 8, p. 569-583
Keywords [en]
Hepatitis C virus, HCV, Guidelines, Direct-acting antiviral agents, Ribavirin, Genotype, People who inject drugs, PWIDs, Children, Chronic kidney disease, HIV, Elimination, Eradication, Resistance associated variants (RAVs), Resistance associated substitutions (RASs)
National Category
Infectious Medicine
Identifiers
URN: urn:nbn:se:oru:diva-68255DOI: 10.1080/23744235.2018.1445281ISI: 000438401700001PubMedID: 29495923Scopus ID: 2-s2.0-85042917462OAI: oai:DiVA.org:oru-68255DiVA, id: diva2:1235734
Available from: 2018-07-27 Created: 2018-07-27 Last updated: 2018-07-27Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records BETA

Duberg, Ann-Sofi

Search in DiVA

By author/editor
Lagging, MartinDuberg, Ann-Sofi
By organisation
School of Medical Sciences
In the same journal
Infectious Diseases
Infectious Medicine

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 78 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf